BR112018011261A2 - ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação? - Google Patents

?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?

Info

Publication number
BR112018011261A2
BR112018011261A2 BR112018011261A BR112018011261A BR112018011261A2 BR 112018011261 A2 BR112018011261 A2 BR 112018011261A2 BR 112018011261 A BR112018011261 A BR 112018011261A BR 112018011261 A BR112018011261 A BR 112018011261A BR 112018011261 A2 BR112018011261 A2 BR 112018011261A2
Authority
BR
Brazil
Prior art keywords
checkpoint inhibitor
individual
methods
treating cancer
prolonging
Prior art date
Application number
BR112018011261A
Other languages
English (en)
Inventor
Law Che-Leung
Field Jessica
Okeley Nicole
Senter Peter
Gardai Shyra
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of BR112018011261A2 publication Critical patent/BR112018011261A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção é dirigida a métodos para o tratamento de câncer compreendendo administrar a um indivíduo com necessidade do mesmo uma quantidade eficaz de 2-desoxi-2-fluoro-l-fucose ou um seu pró-fármaco, ou um sal farmaceuticamente aceitável, do mesmo em combinação com um inibidor de ponto de verificação.
BR112018011261A 2015-12-04 2016-12-02 ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação? BR112018011261A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
BR112018011261A2 true BR112018011261A2 (pt) 2018-11-21

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011261A BR112018011261A2 (pt) 2015-12-04 2016-12-02 ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?

Country Status (13)

Country Link
US (1) US20180353524A1 (pt)
EP (1) EP3383404A4 (pt)
JP (1) JP6906520B2 (pt)
KR (1) KR20180086233A (pt)
CN (1) CN108289903B (pt)
AU (1) AU2016362993A1 (pt)
BR (1) BR112018011261A2 (pt)
CA (1) CA3005997A1 (pt)
EA (1) EA201891340A1 (pt)
IL (1) IL259479B (pt)
MX (1) MX2018006674A (pt)
SG (2) SG10202005298RA (pt)
WO (1) WO2017096274A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190022884A (ko) 2010-08-05 2019-03-06 시애틀 지네틱스, 인크. 푸코스 유사체를 사용한 생체 내에서의 단백질 푸코실화 억제 방법
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
EP3634427A1 (en) * 2017-06-07 2020-04-15 Seattle Genetics, Inc. T cells with reduced surface fucosylation and methods of making and using the same
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
WO2020041541A2 (en) 2018-08-23 2020-02-27 Seattle Genetics, Inc. Anti-tigit antibodies
CN113438951A (zh) * 2018-12-19 2021-09-24 西根股份有限公司 抗体的受控岩藻糖基化
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190022884A (ko) * 2010-08-05 2019-03-06 시애틀 지네틱스, 인크. 푸코스 유사체를 사용한 생체 내에서의 단백질 푸코실화 억제 방법
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака

Also Published As

Publication number Publication date
AU2016362993A1 (en) 2018-07-12
MX2018006674A (es) 2018-11-09
CN108289903A (zh) 2018-07-17
IL259479B (en) 2022-03-01
EA201891340A1 (ru) 2018-11-30
JP2019501145A (ja) 2019-01-17
US20180353524A1 (en) 2018-12-13
EP3383404A4 (en) 2019-07-31
KR20180086233A (ko) 2018-07-30
CN108289903B (zh) 2021-08-03
SG11201804263PA (en) 2018-06-28
IL259479A (en) 2018-07-31
SG10202005298RA (en) 2020-07-29
WO2017096274A1 (en) 2017-06-08
JP6906520B2 (ja) 2021-07-21
CA3005997A1 (en) 2017-06-08
EP3383404A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
BR112018011261A2 (pt) ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?
IL292302B1 (en) Use of glutamate modulating factors in cancer immunotherapy
CY1121925T1 (el) Συνδυαστικη θεραπεια με ενα ενζυμο που αποδομει την υαλουρονανη και εναν αναστολεα σημειων ανοσολογικου ελεγχου
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
BR112017000672A2 (pt) composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112016010271A2 (pt) Anticorpo, composição farmacêutica, método de tratamento, uso de um anticorpo e combinação
CL2017001046A1 (es) Inhibidoes del bromodominio
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112017002263A2 (pt) inibidores de proteína cinase c e métodos de uso dos mesmos
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
ECSP18014798A (es) Inhibidores de ezh2
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
MA40364A (fr) Polythérapie pour le traitement du cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B25E Requested change of name of applicant rejected

Owner name: SEATTLE GENETICS, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870210118851 DE28/12/2021 DEVIDO AO DESPACHO PUBLICADO NA RPI 2660 DE 28/12/2021.